» Articles » PMID: 34934758

Analysis of Risk Factors Associated with Survival in Human Epidermal Growth Factor Receptor 2-positive Ductal Carcinoma Using Korean Breast Cancer Society Database

Overview
Specialty General Surgery
Date 2021 Dec 22
PMID 34934758
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study was performed to identify the risk of mortality in patients diagnosed with human epidermal growth factor receptor 2 (HER2)-positive ductal carcinoma (DCIS).

Methods: We selected 2,592 patients with HER2-positive DCIS from Korean Breast Cancer Society (KBCS) database between January 1997 and December 2019. Patients who received neoadjuvant chemotherapy were excluded. Logistic regression analysis was used to determine the association between clinical factors and overall death after adjusting for tumor and clinical characteristics. Mortality data were modified using the Statistics Korea data.

Results: Thirty deaths (1.2%) were identified out of 2,592 patients in the KBCS database. In the univariate logistic regression analysis, older age, higher body mass index (BMI), type of breast surgery (mastectomy), estrogen receptor-negative, progesterone receptor-negative, and exposure to endocrine therapy were significant clinical factors associated with death. In the multivariate analysis, age (hazard ratio [HR], 1.062; 95% confidence interval [CI], 1.015-1.111; P = 0.006), BMI (HR, 1.179; 95% CI, 1.032-1.347, P = 0.016), breast surgery type (mastectomy lumpectomy; HR, 0.285; 95% CI, 0.096-0.844; P = 0.024), and endocrine therapy (HR, 0.314; 95% CI, 0.099-0.995; P = 0.049) were significant risk factors for mortality.

Conclusion: Advanced age, higher BMI, mastectomy, and the absence of endocrine therapy were factors associated with poor survival of patients with HER2-positive DCIS. This finding requires further validation combined with additional analysis of large databases.

Citing Articles

Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis.

Elshafie S, Trivedi R, Villa-Zapata L, Tackett R, Zaghloul I, Young H Cancer. 2024; 131(1):e35550.

PMID: 39235037 PMC: 11694169. DOI: 10.1002/cncr.35550.

References
1.
Cornfield D, Palazzo J, Schwartz G, Goonewardene S, Kovatich A, Chervoneva I . The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 2004; 100(11):2317-27. DOI: 10.1002/cncr.20260. View

2.
Allred D, Anderson S, Paik S, Wickerham D, Nagtegaal I, Swain S . Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012; 30(12):1268-73. PMC: 3341142. DOI: 10.1200/JCO.2010.34.0141. View

3.
Hoque A, Sneige N, Sahin A, Menter D, Bacus J, Hortobagyi G . Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002; 11(6):587-90. View

4.
Bryan B, Schnitt S, Collins L . Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006; 19(5):617-21. DOI: 10.1038/modpathol.3800570. View

5.
Ross J, Fletcher J . The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998; 16(6):413-28. DOI: 10.1002/stem.160413. View